Chronic Urticaria Part II: Clinical management and therapeutics.

Abstract

Chronic urticaria (CU) is a mast-cell driven disease characterized by recurrent wheals, angioedema, or both, lasting more than six weeks. Timely, appropriate treatment is essential to achieve complete disease control, minimize burden, and improve quality of life. The goal of management is elimination of symptoms with safe, effective therapies at the lowest necessary dose. This two-part continuing medical education series provides a comprehensive review of CU. Part II focuses on the complex management of CU including the role of antihistamines, immunosuppressants, and biologics, as well as novel approaches. The CU therapeutic landscape is evolving, with investigations ongoing for biologics, small molecules, and specific mast cell-directed agents.